Zawidzka E, Biavati L, Thomas A, Zanettini C, Marchionni L, Leone R
J Immunother Cancer. 2025; 13(2).
PMID: 40010772
PMC: 11865787.
DOI: 10.1136/jitc-2024-009367.
Chandora K, Chandora A, Saeed A, Cavalcante L
Cancers (Basel). 2025; 17(3).
PMID: 39941782
PMC: 11815873.
DOI: 10.3390/cancers17030413.
Chih Y, Dietsch A, Koopmann P, Ma X, Agardy D, Zhao B
Nat Commun. 2025; 16(1):1262.
PMID: 39893177
PMC: 11787355.
DOI: 10.1038/s41467-025-56547-w.
Zhu S, Zuo S, Li C, You X, Jiang E, Feng X
J Exp Clin Cancer Res. 2025; 44(1):25.
PMID: 39856752
PMC: 11763111.
DOI: 10.1186/s13046-025-03273-2.
Kuilman T, Schrikkema D, Gadiot J, Gomez-Eerland R, Bies L, Walker J
Nat Commun. 2025; 16(1):649.
PMID: 39809767
PMC: 11733228.
DOI: 10.1038/s41467-024-55420-6.
A multi-kinase inhibitor screen identifies inhibitors preserving stem-cell-like chimeric antigen receptor T cells.
Song F, Tsahouridis O, Stucchi S, Walhart T, Mendell S, Hardy P
Nat Immunol. 2025; 26(2):279-293.
PMID: 39779871
PMC: 11785528.
DOI: 10.1038/s41590-024-02042-1.
Rapidly Manufactured CAR-T with Conserved Cell Stemness and Distinctive Cytokine-Secreting Profile Shows Improved Anti-Tumor Efficacy.
Tsao S, Gu M, Xiong Q, Deng Y, Deng T, Fu C
Vaccines (Basel). 2025; 12(12.
PMID: 39772010
PMC: 11680398.
DOI: 10.3390/vaccines12121348.
Acute Myeloid Leukemia Skews Therapeutic WT1-specific CD8 TCR-T Cells Towards an NK-like Phenotype that Compromises Function and Persistence.
Mazziotta F, Martin L, Eagan D, Bar M, Kinsella S, Paulson K
medRxiv. 2025; .
PMID: 39763516
PMC: 11702715.
DOI: 10.1101/2024.12.13.24318504.
Choice of activation protocol impacts the yield and quality of CAR T cell product, particularly with older individuals.
Mehta P, Trollope G, Leung P, Chinni S, Iasinskaia A, Harrison A
Clin Transl Immunology. 2024; 13(12):e70016.
PMID: 39619015
PMC: 11605362.
DOI: 10.1002/cti2.70016.
Genetically modified and unmodified cellular approaches to enhance graft versus leukemia effect, without increasing graft versus host disease: the use of allogeneic cytokine-induced killer cells.
Rambaldi B, Rizzuto G, Rambaldi A, Introna M
Front Immunol. 2024; 15:1459175.
PMID: 39512351
PMC: 11540647.
DOI: 10.3389/fimmu.2024.1459175.
Tracking Peripheral Memory Cell Subsets in Advanced Nonsmall Cell Lung Cancer Treated with Hypofractionated Radiotherapy and PD-1 Blockade.
Kang P, Yu H, Li Y, Wen X, Ye H, Luo Y
J Oncol. 2024; 2023:3221510.
PMID: 39282224
PMC: 11401694.
DOI: 10.1155/2023/3221510.
Targeting the membrane-proximal C2-set domain of CD33 for improved CAR T cell therapy.
Fiorenza S, Lim S, Laszlo G, Kimble E, Phi T, Lunn-Halbert M
Mol Ther Oncol. 2024; 32(3):200854.
PMID: 39224504
PMC: 11367471.
DOI: 10.1016/j.omton.2024.200854.
Influencing factors and solution strategies of chimeric antigen receptor T-cell therapy (CAR-T) cell immunotherapy.
Wang Z, Zhou L, Wu X
Oncol Res. 2024; 32(9):1479-1516.
PMID: 39220130
PMC: 11361912.
DOI: 10.32604/or.2024.048564.
EBV T-cell immunotherapy generated by peptide selection has enhanced effector functionality compared to LCL stimulation.
Cooper R, Sutherland C, Smith L, Cowan G, Barnett M, Mitchell D
Front Immunol. 2024; 15:1412211.
PMID: 39011042
PMC: 11246990.
DOI: 10.3389/fimmu.2024.1412211.
Novel and multiple targets for chimeric antigen receptor-based therapies in lymphoma.
Pang Y, Ghosh N
Front Oncol. 2024; 14:1396395.
PMID: 38711850
PMC: 11070555.
DOI: 10.3389/fonc.2024.1396395.
Higher TIGIT+ γδ T cells may predict poor prognosis in younger adult patients with non-acute promyelocytic AML.
Hou Q, Wang P, Kong X, Chen J, Yao C, Luo X
Front Immunol. 2024; 15:1321126.
PMID: 38711501
PMC: 11070478.
DOI: 10.3389/fimmu.2024.1321126.
The Confounding Role of Graft-Versus-Host Disease in Animal Models of Cancer Immunotherapy: A Systematic Review.
Ashraf H, Heydarnejad M, Kosari F
Arch Iran Med. 2024; 27(3):159-167.
PMID: 38685841
PMC: 11097315.
DOI: 10.34172/aim.2024.24.
HA-1-targeted T-cell receptor T-cell therapy for recurrent leukemia after hematopoietic stem cell transplantation.
Krakow E, Brault M, Summers C, Cunningham T, Biernacki M, Black R
Blood. 2024; 144(10):1069-1082.
PMID: 38683966
PMC: 11406181.
DOI: 10.1182/blood.2024024105.
Peripheral T Cell Subpopulations as a Potential Surrogate Biomarker during Atezolizumab plus Bevacizumab Treatment for Hepatocellular Carcinoma.
Shirane Y, Fujii Y, Ono A, Nakahara H, Hayes C, Miura R
Cancers (Basel). 2024; 16(7).
PMID: 38611007
PMC: 11011052.
DOI: 10.3390/cancers16071328.
Exploring the evolution of T cell function and diversity across different stages of non-small cell lung cancer.
Chang C, Chang S, Wei Y, Tseng Y, Chou C, Chen Y
Am J Cancer Res. 2024; 14(3):1243-1257.
PMID: 38590421
PMC: 10998748.
DOI: 10.62347/ARYH6451.